5 Things Green Organic Dutchman (TSX:TGOD) Is Doing to Be the Market Leader in Organic Cannabis

Find out how Green Organic Dutchman Holdings Ltd (TSX:TGOD) is creating a niche for itself as the markets leading purveyor of organic cannabis products.

edit Businessman using calculator next to laptop

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Green Organic Dutchman Holdings Ltd (TSX:TGOD) has a unique vision within the market for Canadian cannabis stocks – and that vision is a clear one.

TGOD seeks to become the undisputed market leader for premium organic cannabis products.

Unlike so many other licensed cannabis producers who seem intent on winning the “race to the bottom” as the industry’s lowest cost producer, Green Organic Dutchman’s approach is different.

Rather than being “all about the money” the company feels strongly that by delivering a distinctly superior product, not only will it be able to carve out a niche for itself within what already becoming a crowded marketplace among suppliers and consumers, but it should in theory be able to charge a premium for its product, in turn driving higher margins for its shareholders.

In its most recent investor presentation, TGOD suggest that it expects to achieve a run-rate of production capacity upwards of 200,000 kg annually by Q4 of 2020.

While securing distribution and filling product orders remains a different question altogether, the company already has supply agreements in place with the Ontario Cannabis Retail Corp (OCS) and Velvet Management, one of the country’s largest wine distributors.

Green Organic is hoping that it can capitalize off the recent popularity of health conscious ventures like Whole Foods, which was recently acquired by Amazon.com, Inc. in August of 2017 for more than $13 billion.

But this isn’t just “pie in the sky” type of thinking, either.

Research put forward by the company in its investor presentation suggests that an organic cannabis option would be preferred by 61% of surveyed medical patients and 50% of recreational users. Meanwhile additional research that suggests some of the chemicals and pesticides used in cannabis concentrates run the risk of producing adverse health effects for the drug’s users.

From a financial point of view, there could be certain benefits to the company’s planned business model.

By employing the use of what it calls “hybrid” facilities, the company hopes that it can keep a lid on operating costs while also lowering the requirement for capital investments compared to conventional indoor grow facilities thanks to advanced technologies designed to take advantage of natural lighting and enhanced humidity, environmental and temperature controls.

Looking ahead to the future, Organic Dutchman has already entered into a strategic joint venture dedicated toward the Latin American market, estimated at US$9.8 billion annually and has also created a partnership with multi-billion dollar food processor Symrise that will see two create a U.S.-based beverage innovation company.

Foolish bottom line

Currently trading at a market capitalization of $875 million, the Green Dutchman is valued at considerably less than larger rivals like Canopy Growth Corp, Aurora Cannabis Inc and even Hexo Corp.

Yet prospective investors in the company’s stock shouldn’t exactly be expecting those fortunes to be changing anytime soon.

Make no mistake, this is an interesting play for cannabis investors seeking something a little different and off the beaten path, but until proven otherwise, the market for organic cannabis products – and TGOD stock – shouldn’t be treated any differently than a niche segment within the broader cannabis markets.

Making the world smarter, happier, and richer.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Jason Phillips has no position in any of the stocks mentioned. David Gardner owns shares of Amazon. The Motley Fool owns shares of Amazon.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »